An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Neuronetics, Inc. (NASDAQ: STIM) will report its first-quarter 2024 financial and operating results on May 7th, 2024, followed by a conference call to discuss the outcomes. The company focuses on developing medical technology products to enhance the lives of patients with neurohealth disorders.
Neuronetics, Inc. (NASDAQ: STIM) comunicherà i risultati finanziari e operativi del primo trimestre del 2024 il 7 maggio 2024, seguiti da una conferenza telefonica per discutere i risultati. L'azienda si concentra sullo sviluppo di prodotti tecnologici medici per migliorare la vita dei pazienti affetti da disturbi neurologici.
Neuronetics, Inc. (NASDAQ: STIM) reportará sus resultados financieros y operativos del primer trimestre de 2024 el 7 de mayo de 2024, seguido por una llamada de conferencia para discutir los resultados. La compañía se enfoca en desarrollar productos de tecnología médica para mejorar la vida de los pacientes con trastornos neurosalud.
Neuronetics, Inc. (나스닥: STIM)는 2024년 5월 7일에 2024년 첫 번째 분기 재정 및 운영 결과를 보고한 후 결과에 대해 논의하기 위한 컨퍼런스 콜을 진행할 예정입니다. 이 회사는 신경 건강 장애를 가진 환자들의 삶을 향상시키기 위해 의료 기술 제품 개발에 중점을 두고 있습니다.
Neuronetics, Inc. (NASDAQ: STIM) rapportera ses résultats financiers et opérationnels pour le premier trimestre de 2024 le 7 mai 2024, suivi d'une conférence téléphonique pour discuter des résultats. La société se concentre sur le développement de produits de technologie médicale pour améliorer la vie des patients atteints de troubles neurologiques.
Neuronetics, Inc. (NASDAQ: STIM) wird am 7. Mai 2024 die Finanz- und Betriebsergebnisse für das erste Quartal 2024 bekanntgeben, gefolgt von einer Telefonkonferenz zur Diskussion der Ergebnisse. Das Unternehmen konzentriert sich auf die Entwicklung medizintechnischer Produkte zur Verbesserung des Lebens von Patienten mit neurogesundheitlichen Störungen.
Positive
None.
Negative
None.
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar is also indicated as a first-line, adjunct for MDD in adolescents 15 and older. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.1 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact: Mike Vallie or Mark Klausner ICR Westwicke 443-213-0499 ir@neuronetics.com
Media Contact: EvolveMKD 646-517-4220 NeuroStar@evolvemkd.com
FAQ
When will Neuronetics report its first-quarter 2024 financial and operating results?
Neuronetics will report its first-quarter 2024 financial and operating results on May 7th, 2024.
What is Neuronetics' ticker symbol?
Neuronetics' ticker symbol is STIM.
How can I listen to the conference call discussing Neuronetics' results?
The conference call discussing Neuronetics' results will be broadcast live via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs.
with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.
